Germany to boost the bioeconomyShortly before the Global Bioeconomy Summit (19.-20.4.2018) in Berlin will begin, Germany’s new Research Minister Anja Karliczek announced three major initiatives to strengthen the biologisation of the … more ➔
Canopy acquires Czech Annabis Medical sro Canopy Growth Corp. is growing its medical cannabis business in Europe with the acquisition of Czech market leader Annabis Medical sro. more ➔
New Pierre Guerin site in Hildesheim, Germ...Mid last year, the company Pierre Guerin has opened a new location in Germany, Hildesheim. more ➔
GSK pass orphan gene therapy assets to Orc...British drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. … more ➔
Alexion in €639m bid for Wilson Therapeu...A public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics Board of Directors. Alexions SEK232/share bid would total in an acqusition price … more ➔
Novartis enters SMA race acquiring AveXis... Swiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis … more ➔
Blood test predincting Alzheimer’s p...A newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis. more ➔
Poor investigator brochures: Resarchers ca...Human drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by … more ➔
Ose and Boehringer ink €1.1bn deal in im...French Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio … more ➔
Cellectis in offering of US$175m ADS follo...French allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of … more ➔
